New combo shows promise for tough lymphomas

NCT ID NCT02213913

Completed Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting worse. The trial is complete, and results help guide future treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide
What this could lead to: If successful, this combination could offer a more effective treatment option for aggressive B-cell lymphomas with MYC gene changes.
What could go wrong: This is an early-phase trial with only 55 participants, so results may not apply to all patients. Side effects from the chemotherapy combination can be severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma follicular lymphoma grade III lymphomatoid granulomatosis hairy cell leukemia high-grade B-cell lymphoma double-hit/triple-hit Hodgkin's lymphoma, mixed cellularity Hodgkins lymphoma intraocular lymphoma large-cell immunoblastic lymphoma Lymphoma, B-Cell, Marginal Zone MALT lymphoma mantle cell lymphoma marginal zone lymphoma nodal marginal zone B-cell lymphoma non-Hodgkin lymphoma primary cutaneous B-cell lymphoma small intestine lymphoma splenic marginal zone lymphoma testicular lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Decatur Memorial Hospital Cancer Care Institute

Decatur, Illinois, 62526, United States
Illinois Cancer Care

Peoria, Illinois, 61615, United States
NorthShore University HealthSystem

Evanston, Illinois, 60201, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Maryland

Baltimore, Maryland, 21202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.